TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework to help clinicians weigh obesity medications, including GLP-1 therapies, for older adults. It calls for assessing function, nutrition and cognition before treatment and pairing medication with measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to guide clinicians considering obesity medications for older adults, including GLP-1 therapies. The guidance emphasizes assessing each patient’s function, nutrition and cognition before treatment, reflecting concerns about frailty, muscle loss and limited representation of older people in clinical trials.
The paper, developed by the AGS Healthy Aging Special Interest Group and published in the Journal of the American Geriatrics Society, applies the Geriatrics 5Ms Framework to incretin-based obesity treatment. Its five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most, offering clinicians a structure for considering a patient’s health, daily function, treatment burden and priorities rather than focusing on weight alone.
The authors recommend a pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. They also highlight age-related concerns including sarcopenia, frailty, lean muscle loss, malnutrition and dehydration. The report says obesity medicines may offer benefits for weight management, glycemic control and other health conditions, while noting that older adults are underrepresented in clinical trials.
The framework recommends pairing medication with supportive measures, including resistance training and adequate dietary protein. For some patients, the authors say a team-based plan may be appropriate, with support from professionals such as a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The report presents these as clinical considerations, not as a one-size-fits-all prescription.
Balancing Weight Treatment With Function
The framework addresses a practical tension in prescribing: a medication’s potential benefits need to be weighed against the needs and vulnerabilities of an older patient. Concerns such as muscle loss, frailty and inadequate nutrition can affect mobility and independence, so evaluating functional and nutritional status may help clinicians make decisions that better reflect a person’s overall health.
Its patient-centered approach also puts individual priorities into the conversation. The 5Ms structure encourages consideration of cognition, mobility, other medications and complex health needs alongside the outcomes that matter to the patient. That may help clinicians and patients discuss whether treatment fits their goals and what additional support may be needed.
The paper is a framework for clinical decision-making, not evidence that a particular medicine is safe or effective for every older adult. Its emphasis on assessment and co-interventions makes clear that prescribing is only one part of care; nutrition, exercise capacity and follow-up also matter.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
Therabody Theragun Mini 3rd Generation Massage Gun, Black
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
Why Geriatric Factors Matter
The report focuses on incretin therapies, a group that includes GLP-1 medications acting through gut-derived hormonal pathways. It describes these medicines as offering promising benefits for weight management, blood sugar control and other health conditions. However, the authors point to a key evidence limitation: older adults are underrepresented in clinical trials, making it harder to apply trial findings directly across the diverse health circumstances of older patients.
Rather than treating age alone as a prescribing rule, the framework centers on factors that can differ substantially from one person to another. Frailty, nutritional status and functional ability are among the considerations it asks clinicians to assess. The case-based format is intended to show how the 5Ms can inform decisions in practice.
The article is by Elias M. Wisdom and colleagues and appeared in the Journal of the American Geriatrics Society in 2026. Its citation lists the title as “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing” and gives DOI 10.1111/jgs.70769.
“The framework applies the Geriatrics 5Ms: Mind, Mobility, Medications, Multicomplexity, and Matters Most.”
— The American Geriatrics Society framework, as described in the report
Evidence Gaps in Older Patients
The report does not establish how well individual obesity medications work across different groups of older adults or provide a single prescribing regimen for them. Its account notes that older adults are underrepresented in clinical trials, leaving questions about how evidence applies to patients with frailty, multiple health conditions or nutritional challenges.
The supplied report also does not provide trial results, medication-specific risk estimates, dosing recommendations or detailed monitoring schedules. It does not state how often clinicians should reassess patients, or which older adults are most likely to benefit. Those points cannot be inferred from the framework summary alone.
The authors’ approach calls for individual assessment, but the available information does not say how widely the framework will be adopted or whether future research will test its use in clinical practice. Decisions about a specific medication remain matters for patients and their clinicians.
Applying the Framework in Care
The paper is now available in the Journal of the American Geriatrics Society, giving clinicians a case-based structure to consider when discussing obesity medications with older patients. In practice, the framework points toward checking function, nutrition and cognition before treatment and discussing supportive measures such as resistance exercise and adequate protein.
For some patients, the authors suggest that care may involve a multidisciplinary team, including nutrition, physical therapy, fitness or behavioral health expertise. The source material does not announce a formal implementation program, a follow-up study or a specific next publication. How clinicians use the framework, and whether additional evidence will address trial representation and outcomes in older adults, remain open questions.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians considering obesity medications in older adults. It uses the Geriatrics 5Ms to support patient-centered prescribing decisions.
Which factors should clinicians assess before treatment?
The framework calls for assessing functional status, nutritional adequacy and cognitive impairment. It also highlights concerns such as frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
Does the framework recommend medication alone?
No. It recommends pairing treatment with supportive measures such as resistance training and adequate dietary protein. The authors say some older adults may benefit from a team-based approach.
Does the paper prove obesity medicines are safe for all older adults?
No. The paper offers a clinical decision framework, not proof that a particular medication is safe or appropriate for every older person. The report also notes that older adults are underrepresented in clinical trials.
Where was the framework published?
The paper by Elias M. Wisdom and colleagues was published in the Journal of the American Geriatrics Society in 2026. Its DOI is 10.1111/jgs.70769.
Source: medicalxpress.com
